Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas

Pritha Paul, Lauren A. Gillory, Junghee Kang, Jingbo Qiao, Dai H. Chung

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The overall survival for neuroblastoma remains dismal, in part due to the emergence of resistance to chemotherapeutic drugs. We have demonstrated that gastrin-releasing peptide (GRP), a gut peptide secreted by neuroblastoma, acts as an autocrine growth factor. We hypothesized that knockdown of GRP will induce apoptosis in neuroblastoma cells and potentiate the cytotoxic effects of chemotherapeutic agents. Methods: The human neuroblastoma cell lines (JF, SK-N-SH) were transfected with small interfering (si) RNA targeted at GRP. Apoptosis was assessed by DNA fragmentation assay. Immunoblotting was used to confirm molecular markers of apoptosis, and flow cytometry was performed to determine cell cycle arrest after GRP knockdown. Results: siGRP resulted in an increase in apoptosis in the absence of chemotherapeutic interventions. A combination of GRP silencing and chemotherapeutic drugs resulted in enhanced apoptosis when compared to either of the treatments alone. GRP silencing led to increased expression of proapoptotic proteins, p53 and p21. Conclusion: Silencing of GRP induces apoptosis in neuroblastoma cells; it acts synergistically with chemotherapeutic effects of etoposide and vincristine. GRP knockdown-mediated apoptosis appears to be associated with upregulation of p53 in neuroblastoma cells. Targeting GRP may be postulated as a potential novel agent for combinational treatment to treat aggressive neuroblastomas.

Original languageEnglish (US)
Pages (from-to)425-432
Number of pages8
JournalSurgery
Volume149
Issue number3
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Gastrin-Releasing Peptide
Neuroblastoma
Apoptosis
Vincristine
DNA Fragmentation
Etoposide
Cell Cycle Checkpoints
Immunoblotting
Pharmaceutical Preparations
Small Interfering RNA
Intercellular Signaling Peptides and Proteins
Flow Cytometry
Up-Regulation
Cell Line

ASJC Scopus subject areas

  • Surgery

Cite this

Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas. / Paul, Pritha; Gillory, Lauren A.; Kang, Junghee; Qiao, Jingbo; Chung, Dai H.

In: Surgery, Vol. 149, No. 3, 01.03.2011, p. 425-432.

Research output: Contribution to journalArticle

Paul, Pritha ; Gillory, Lauren A. ; Kang, Junghee ; Qiao, Jingbo ; Chung, Dai H. / Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas. In: Surgery. 2011 ; Vol. 149, No. 3. pp. 425-432.
@article{fe2b81a5adf542438cc32c65c2797e5d,
title = "Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas",
abstract = "Background: The overall survival for neuroblastoma remains dismal, in part due to the emergence of resistance to chemotherapeutic drugs. We have demonstrated that gastrin-releasing peptide (GRP), a gut peptide secreted by neuroblastoma, acts as an autocrine growth factor. We hypothesized that knockdown of GRP will induce apoptosis in neuroblastoma cells and potentiate the cytotoxic effects of chemotherapeutic agents. Methods: The human neuroblastoma cell lines (JF, SK-N-SH) were transfected with small interfering (si) RNA targeted at GRP. Apoptosis was assessed by DNA fragmentation assay. Immunoblotting was used to confirm molecular markers of apoptosis, and flow cytometry was performed to determine cell cycle arrest after GRP knockdown. Results: siGRP resulted in an increase in apoptosis in the absence of chemotherapeutic interventions. A combination of GRP silencing and chemotherapeutic drugs resulted in enhanced apoptosis when compared to either of the treatments alone. GRP silencing led to increased expression of proapoptotic proteins, p53 and p21. Conclusion: Silencing of GRP induces apoptosis in neuroblastoma cells; it acts synergistically with chemotherapeutic effects of etoposide and vincristine. GRP knockdown-mediated apoptosis appears to be associated with upregulation of p53 in neuroblastoma cells. Targeting GRP may be postulated as a potential novel agent for combinational treatment to treat aggressive neuroblastomas.",
author = "Pritha Paul and Gillory, {Lauren A.} and Junghee Kang and Jingbo Qiao and Chung, {Dai H.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1016/j.surg.2010.08.011",
language = "English (US)",
volume = "149",
pages = "425--432",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas

AU - Paul, Pritha

AU - Gillory, Lauren A.

AU - Kang, Junghee

AU - Qiao, Jingbo

AU - Chung, Dai H.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: The overall survival for neuroblastoma remains dismal, in part due to the emergence of resistance to chemotherapeutic drugs. We have demonstrated that gastrin-releasing peptide (GRP), a gut peptide secreted by neuroblastoma, acts as an autocrine growth factor. We hypothesized that knockdown of GRP will induce apoptosis in neuroblastoma cells and potentiate the cytotoxic effects of chemotherapeutic agents. Methods: The human neuroblastoma cell lines (JF, SK-N-SH) were transfected with small interfering (si) RNA targeted at GRP. Apoptosis was assessed by DNA fragmentation assay. Immunoblotting was used to confirm molecular markers of apoptosis, and flow cytometry was performed to determine cell cycle arrest after GRP knockdown. Results: siGRP resulted in an increase in apoptosis in the absence of chemotherapeutic interventions. A combination of GRP silencing and chemotherapeutic drugs resulted in enhanced apoptosis when compared to either of the treatments alone. GRP silencing led to increased expression of proapoptotic proteins, p53 and p21. Conclusion: Silencing of GRP induces apoptosis in neuroblastoma cells; it acts synergistically with chemotherapeutic effects of etoposide and vincristine. GRP knockdown-mediated apoptosis appears to be associated with upregulation of p53 in neuroblastoma cells. Targeting GRP may be postulated as a potential novel agent for combinational treatment to treat aggressive neuroblastomas.

AB - Background: The overall survival for neuroblastoma remains dismal, in part due to the emergence of resistance to chemotherapeutic drugs. We have demonstrated that gastrin-releasing peptide (GRP), a gut peptide secreted by neuroblastoma, acts as an autocrine growth factor. We hypothesized that knockdown of GRP will induce apoptosis in neuroblastoma cells and potentiate the cytotoxic effects of chemotherapeutic agents. Methods: The human neuroblastoma cell lines (JF, SK-N-SH) were transfected with small interfering (si) RNA targeted at GRP. Apoptosis was assessed by DNA fragmentation assay. Immunoblotting was used to confirm molecular markers of apoptosis, and flow cytometry was performed to determine cell cycle arrest after GRP knockdown. Results: siGRP resulted in an increase in apoptosis in the absence of chemotherapeutic interventions. A combination of GRP silencing and chemotherapeutic drugs resulted in enhanced apoptosis when compared to either of the treatments alone. GRP silencing led to increased expression of proapoptotic proteins, p53 and p21. Conclusion: Silencing of GRP induces apoptosis in neuroblastoma cells; it acts synergistically with chemotherapeutic effects of etoposide and vincristine. GRP knockdown-mediated apoptosis appears to be associated with upregulation of p53 in neuroblastoma cells. Targeting GRP may be postulated as a potential novel agent for combinational treatment to treat aggressive neuroblastomas.

UR - http://www.scopus.com/inward/record.url?scp=79951943908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951943908&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2010.08.011

DO - 10.1016/j.surg.2010.08.011

M3 - Article

C2 - 21035156

AN - SCOPUS:79951943908

VL - 149

SP - 425

EP - 432

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 3

ER -